Research programme: RSV-influenza combination vaccine - Novavax

Drug Profile

Research programme: RSV-influenza combination vaccine - Novavax

Alternative Names: Combination seasonal influenza-RSV nanoparticle vaccine - Novavax; Combination seasonal influenza-RSV vaccine - Novavax; Combo RSV/Flu vaccine - Novavax; RSV-influenza nanoparticle vaccine - Novavax; RSV-influenza vaccine - Novavax; RSV/Flu vaccine - Novavax

Latest Information Update: 08 Jun 2016

Price : $50

At a glance

  • Originator Novavax
  • Class Influenza virus vaccines; Protein-vaccines; Recombinant fusion proteins; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 02 Jun 2016 Novavax plans a phase I/II trial for Influenza viral infections in USA
  • 12 Mar 2014 Preclinical trials in Respiratory syncytial virus infections (prevention) in USA (Parenteral)
  • 12 Mar 2014 Preclinical trials in Influenza virus infections (prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top